Giant cell arteritis patients may be able to reduce treatment, study suggests
NCT ID NCT07108387
First seen Jan 04, 2026 · Last updated Jun 18, 2026 · Updated 32 times
Summary
This study looks at whether people with giant cell arteritis (GCA) who are in remission can safely stop or lower their dose of tocilizumab (Actemra). About 78 adults who have been on high-dose tocilizumab for at least a year and off steroids for three months will either stop the drug or take a lower dose. Researchers will track how many have a disease flare over 18 months to find the best long-term management strategy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS (GCA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory University School of Medicine: Division of Rheumatology
RECRUITINGAtlanta, Georgia, 30307, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hospital for Special Surgery, New York: Division of Rheumatology
NOT_YET_RECRUITINGNew York, New York, 10021, United States
-
Johns Hopkins Hospital: Division of Rheumatology Vasculitis Center
RECRUITINGBaltimore, Maryland, 21287, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases
RECRUITINGBoston, Massachusetts, 02114, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Northwell Health: Division of Rheumatology and Allergy-Clinical Immunology
RECRUITINGGreat Neck, New York, 11021, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwestern University
RECRUITINGChicago, Illinois, 60611, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Pittsburgh Medical Center: Division of Rheumatology and Clinical Immunology
RECRUITINGPittsburgh, Pennsylvania, 15217, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.